Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
FEBS J ; 291(3): 489-509, 2024 02.
Article in English | MEDLINE | ID: mdl-37724442

ABSTRACT

Sustained cardiac hypertrophy damages the heart and weakens cardiac function, often leading to heart failure and even death. Pathological cardiac hypertrophy has become a central therapeutic target for many heart diseases including heart failure. However, the underlying mechanisms of cardiac hypertrophy, especially the involvement of autophagy program, are still ill-understood. Synaptotagmin-7 (Syt7), a multifunctional and high-affinity calcium sensor, plays a pivotal role in asynchronous neurotransmitter release, synaptic facilitation, and vesicle pool regulation during synaptic transmission. However, little is known about whether Syt7 is expressed in the myocardium and involved in the pathogenesis of heart diseases. Here we showed that Syt7 was significantly upregulated in Ang II-treated hearts and cardiomyocytes. Homozygous syt7 knockout (syt7-/-) mice exhibited significantly attenuated cardiac hypertrophy and fibrosis and improved cardiac function. We further found that Syt7 exerted a pro-hypertrophic effect by suppressing the autophagy process. In exploring the upstream mechanisms, microRNA (miR)-93 was identified to participate in the regulation of Syt7 expression. miR-93 protected hearts against Ang II-induced hypertrophy through targeting Syt7-autophagy pathway. In summary, our data reveal a new cardiac hypertrophy regulator and a novel hypertrophy regulating model composed of miR-93, Syt7 and autophagy program. These molecules may serve as potential therapeutic targets in the treatment of cardiac hypertrophy and heart failure.


Subject(s)
Heart Failure , MicroRNAs , Mice , Animals , Synaptotagmins/genetics , Synaptotagmins/metabolism , Synaptotagmins/pharmacology , Cardiomegaly/metabolism , Myocytes, Cardiac/metabolism , Heart Failure/complications , Autophagy/genetics , MicroRNAs/genetics , MicroRNAs/metabolism , Angiotensin II/genetics
2.
Environ Toxicol ; 38(8): 1891-1904, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37195900

ABSTRACT

Cerebral ischemia/reperfusion (I/R) injury remains a grievous health threat, and herein effective therapy is urgently needed. This study explored the protection of neuroglobin (Ngb) in rats with cerebral I/R injury. The focal cerebral I/R rat models were established by middle cerebral artery occlusion (MCAO) and neuronal injury models were established by oxygen-glucose deprivation/reoxygenation (OGD/R) treatment. The brain injury of rats was assessed. Levels of Ngb, Bcl-2, Bax, endoplasmic reticulum stress (ERS)-related markers, and Syt1 were measured by immunofluorescence staining and Western blotting. The cytotoxicity in neurons was assessed by lactate dehydrogenase (LDH) release assay. Levels of intracellular Ca2+ and mitochondrial function-related indicators were determined. The binding between Ngb and Syt1 was detected by co-immunoprecipitation. Ngb was upregulated in cerebral I/R rats and its overexpression alleviated brain injury. In OGD/R-induced neurons, Ngb overexpression decreased LDH level and neuronal apoptosis, decreased Ca2+ content, and mitigated mitochondrial dysfunction and ERS-related apoptosis. However, Ngb silencing imposed the opposite effects. Importantly, Ngb could bind to Syt1. Syt1 knockdown partially counteracted the alleviation of Ngb on OGD/R-induced injury in neurons and cerebral I/R injury in rats. Briefly, Ngb extenuated cerebral I/R injury by repressing mitochondrial dysfunction and endoplasmic reticulum stress-mediated neuronal apoptosis through Syt1.


Subject(s)
Brain Ischemia , Reperfusion Injury , Rats , Animals , Neuroglobin/metabolism , Neuroglobin/pharmacology , Neurons , Apoptosis , Brain Ischemia/metabolism , Reperfusion Injury/prevention & control , Reperfusion Injury/metabolism , Endoplasmic Reticulum Stress , Mitochondria/metabolism , Synaptotagmins/metabolism , Synaptotagmins/pharmacology , Glucose/metabolism
3.
Biomed J ; 45(2): 387-395, 2022 04.
Article in English | MEDLINE | ID: mdl-34326021

ABSTRACT

BACKGROUND: Nitrite stimulates insulin secretion from pancreatic ß-cells; however, the underlying mechanisms have not been completely addressed. The aim of this study is to determine effect of nitrite on gene expression of SNARE proteins involved in insulin secretion from isolated pancreatic islets in Type 2 diabetic Wistar rats. METHODS: Three groups of rats were studied (n = 10/group): Control, diabetes, and diabetes + nitrite, which treated with sodium nitrite (50 mg/L) for 8 weeks. Type 2 diabetes was induced using a low-dose of streptozotocin (25 mg/kg) combined with high-fat diet. At the end of the study, pancreatic islets were isolated and mRNA expressions of interested genes were measured; in addition, protein expression of proinsulin and C-peptide in pancreatic tissue was assessed using immunofluorescence staining. RESULTS: Compared with controls, in the isolated pancreatic islets of Type 2 diabetic rats, mRNA expression of glucokinase (59%), syntaxin1A (49%), SNAP25 (70%), Munc18b (48%), insulin1 (56%), and insulin2 (52%) as well as protein expression of proinsulin and C-peptide were lower. In diabetic rats, nitrite administration significantly increased gene expression of glucokinase, synaptotagmin III, syntaxin1A, SNAP25, Munc18b, and insulin genes as well as increased protein expression of proinsulin and C-peptide. CONCLUSION: Stimulatory effect of nitrite on insulin secretion in Type 2 diabetic rats is at least in part due to increased gene expression of molecules involved in glucose sensing (glucokinase), calcium sensing (synaptotagmin III), and exocytosis of insulin vesicles (syntaxin1A, SNAP25, and Munc18b) as well as increased expression of insulin genes.


Subject(s)
Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Islets of Langerhans , Animals , C-Peptide/genetics , C-Peptide/metabolism , C-Peptide/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/metabolism , Gene Expression , Glucokinase/genetics , Glucokinase/metabolism , Glucokinase/pharmacology , Glucose/metabolism , Humans , Insulin Secretion , Islets of Langerhans/metabolism , Male , Nitrites/metabolism , Nitrites/pharmacology , Proinsulin/genetics , Proinsulin/metabolism , Proinsulin/pharmacology , RNA, Messenger , Rats , Rats, Wistar , Synaptotagmins/genetics , Synaptotagmins/metabolism , Synaptotagmins/pharmacology
4.
J Neurochem ; 159(4): 729-741, 2021 11.
Article in English | MEDLINE | ID: mdl-34599505

ABSTRACT

Recent work has revealed that spontaneous release plays critical roles in the central nervous system, but how it is regulated remains elusive. Here, we report that synaptotagmin-11 (Syt11), a Ca2+ -independent Syt isoform associated with schizophrenia and Parkinson's disease, suppressed spontaneous release. Syt11-knockout hippocampal neurons showed an increased frequency of miniature excitatory post-synaptic currents while over-expression of Syt11 inversely decreased the frequency. Neither knockout nor over-expression of Syt11 affected the average amplitude, suggesting the pre-synaptic regulation of spontaneous neurotransmission by Syt11. Glutathione S-transferase pull-down, co-immunoprecipitation, and affinity-purification experiments demonstrated a direct interaction of Syt11 with vps10p-tail-interactor-1a (vti1a), a non-canonical SNARE protein that maintains spontaneous release. Importantly, knockdown of vti1a reversed the phenotype of Syt11 knockout, identifying vti1a as the main target of Syt11 inhibition. Domain analysis revealed that the C2A domain of Syt11 bound vti1a with high affinity. Consistently, expression of the C2A domain alone rescued the phenotype of elevated spontaneous release in Syt11-knockout neurons similar to the full-length protein. Altogether, our results suggest that Syt11 inhibits vti1a-containing vesicles during spontaneous release.


Subject(s)
Qb-SNARE Proteins/drug effects , Synaptic Transmission/drug effects , Synaptotagmins/pharmacology , Animals , Electrophysiological Phenomena , Excitatory Postsynaptic Potentials , Gene Knock-In Techniques , Hippocampus/pathology , Immunoprecipitation , Mice , Mice, Inbred C57BL , Mice, Knockout , Neurons/pathology , Primary Cell Culture
5.
J Biol Chem ; 282(36): 26335-43, 2007 Sep 07.
Article in English | MEDLINE | ID: mdl-17613520

ABSTRACT

Regulated secretion is a fundamental process underlying the function of many cell types. In particular, acrosomal exocytosis in mammalian sperm is essential for egg fertilization. Regulated secretion requires SNARE proteins and, in neurons, also synaptotagmin I and complexin. Recent reports suggest that complexin imposes a fusion block that is released by Ca(2+) and synaptotagmin I. However, no direct evidence for this model in secreting cells has been provided and whether this complexin/synaptotagmin interplay functions in other types of secretion is unknown. In this report, we show that the C2B domain of synaptotagmin VI and an anti-complexin antibody blocked the formation of trans SNARE complexes in permeabilized human sperm, and that this effect was reversed by adding complexin. In contrast, an excess of complexin stopped exocytosis at a later step, when SNAREs were assembled in loose trans complexes. Interestingly, this blockage was released by the addition of the synaptotagmin VI C2B domain in the presence of Ca(2+). We have previously demonstrated that the activity of this domain is regulated by protein kinase C-mediated phosphorylation. Here, we show that a phosphomimetic mutation in the polybasic region of the C2B domain strongly affects its Ca(2+) and phospholipids binding properties. Importantly, this mutation completely abrogates its ability to rescue the complexin block. Our results show that the functional interplay between complexin and synaptotagmin has a central role in a physiological secretion event, and that this interplay can be modulated by phosphorylation of the C2B domain.


Subject(s)
Acrosome/metabolism , Exocytosis/physiology , Nerve Tissue Proteins/metabolism , Synaptotagmin I/metabolism , Synaptotagmins/metabolism , Adaptor Proteins, Vesicular Transport , Animals , Calcium/metabolism , Exocytosis/drug effects , Fertilization/physiology , Humans , Male , Nerve Tissue Proteins/pharmacology , Phosphorylation/drug effects , Protein Binding/physiology , Protein Structure, Tertiary/physiology , Rats , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Synaptotagmin I/pharmacology , Synaptotagmins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...